Lead Product(s): IMU-856
Therapeutic Area: Gastroenterology
Highest Development Status: Preclinical Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2020
The option and license agreement gives Immunic the exclusive rights to commercialization of IMU-856 in all countries.